US2018265511A1PendingUtilityA1

Compounds and compositions for treating chemical warfare agent-induced injuries

Assignee: HYDRA BIOSCIENCES INCPriority: May 14, 2008Filed: Mar 15, 2018Published: Sep 20, 2018
Est. expiryMay 14, 2028(~1.8 yrs left)· nominal 20-yr term from priority
A61K 31/519C07D 473/04
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.

Claims

exact text as granted — not AI-modified
1 . A method of treating an injury to the skin or respiratory tract resulting from exposure to a chemical warfare agent, the method comprising administering to a subject an effective amount of a compound of Formula (I) or a salt thereof: 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is H; 
         R 2  is H or C 1 -C 6  alkyl; 
         L is C(O)NR 6 ; 
         R 3  is nitrogen-containing heteroaryl substituted with R 7 ; 
         R 6  is H; 
         R 7  is heteroaryl substituted with 1-3 R 8 ; 
         each R 8  is independently cyclyl or heterocyclyl; 
         wherein said cyclyl or heterocyclyl can be substituted at one or more positions with halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF 3 , or —CN; 
         R 9  is H; 
         R 11  is H; 
         R 12  is C 1 -C 6  alkyl; 
         m is 1; and 
         n is 0. 
       
     
     
         2 . A method of treating an injury to the skin or respiratory tract resulting from exposure to a chemical warfare agent, the method comprising administering to a subject an effective amount of a compound of Formula (I) or a salt thereof: 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is H or C 1 -C 6  alkyl; 
         R 2  is H; 
         L is C(O)NR 6 ; 
         R 3  is nitrogen-containing heteroaryl substituted with R 7 ; 
         R 6  is H; 
         R 7  is heteroaryl substituted with 1-3 R 8 ; 
         each R 8  is independently cyclyl or heterocyclyl; 
         wherein said cyclyl or heterocyclyl can be substituted at one or more positions with halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF 3 , or —CN; 
         R 9  is H; 
         R 11  is H; 
         R 12  is C 1 -C 6  alkyl; 
         m is 1; and 
         n is 0. 
       
     
     
         3 . The method of  claim 1 , wherein the compound is administered orally, via intramuscular injection, or topically. 
     
     
         4 . The method of  claim 1 , wherein the chemical warfare agent is tear gas. 
     
     
         5 . The method of  claim 1 , wherein the chemical warfare agent is chlorine. 
     
     
         6 . The method of  claim 1 , wherein the chemical warfare agent is mustard gas. 
     
     
         7 . The method of  claim 1 , wherein the subject is a human. 
     
     
         8 . The method of  claim 2 , wherein the compound is administered orally, via intramuscular injection, or topically. 
     
     
         9 . The method of  claim 2 , wherein the chemical warfare agent is tear gas. 
     
     
         10 . The method of  claim 2 , wherein the chemical warfare agent is chlorine. 
     
     
         11 . The method of  claim 2 , wherein the chemical warfare agent is mustard gas. 
     
     
         12 . The method of  claim 2 , wherein the subject is a human.

Join the waitlist — get patent alerts

Track US2018265511A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.